|Day Low/High||35.34 / 36.88|
|52 Wk Low/High||11.57 / 116.75|
Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc.
In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $33.14, changing hands for $33.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...
But, Jim Cramer says, he thinks Elon Musk's solar shingles look really nice.
Investors need to sift through the confusing crosswinds hitting the market, Jim Cramer says.
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick Mahaffy, the Company's President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm MST.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.
Jim Cramer says he doesn't like solar companies, but ICE is cool. Cable stocks, he says, are underrated.
Staying home is the new going out, and these companies are profiting, Cramer says.
Many traders follow trends, but these can change quickly, sending a stock plummeting. There are signals that will help a trader know how to avoid this type of pattern.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
Clovis Oncology (CLVS) gave an update on a clinical trial for its rucaparib drug on Friday, showing its candidate might be inferior to competitors.
Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.
Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
Deutsche Bank's problems have investors worried about another Lehman failure, Cramer says.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from its rucaparib program in ovarian cancer will be presented at the annual European Society for Medical Oncology (ESMO) 2016 Congress.
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
Cramer is sticking with Weyerhaeuser and thinks Taser is a buy.
Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.
The technical signs indicate the stock's price and volume are going up without a dip.
Clovis Oncology's (CLVS) stock rating was lifted to 'outperform' at Credit Suisse on takeover talk.
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
Here are Wednesday's top research calls, including an upgrade for Clovis Oncology, downgrades for Sketchers USA and Wells Fargo and new coverage for Altria.